Voranigo contains the active ingredient vorasidenib, an oral targeted therapy classified as an IDH1 and IDH2 inhibitor. It is indicated for the treatment of adults and eligible pediatric patients with grade 2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation following surgery. These tumors belong to a group of primary brain cancers known as diffuse gliomas.

Vorasidenib works by selectively inhibiting mutated IDH1 and IDH2 enzymes, which can produce abnormal metabolites that contribute to tumor development and growth. By blocking these mutant enzymes, Voranigo helps reduce the production of the oncometabolite 2-hydroxyglutarate (2-HG), slowing tumor progression and helping preserve neurological function.

The medication is administered orally as a once-daily tablet and is designed to penetrate the blood-brain barrier, allowing it to reach tumor cells within the central nervous system. Treatment is typically continued until disease progression or unacceptable toxicity occurs.

Clinical studies have demonstrated that Voranigo can significantly prolong progression-free survival and delay the need for additional interventions in patients with IDH-mutant low-grade gliomas. Its approval represents an important advancement in precision medicine for brain tumor treatment.

Common side effects may include fatigue, headache, diarrhea, nausea, COVID-19 infection, muscle pain, and elevated liver enzymes. Patients receiving Voranigo should undergo regular monitoring of liver function and other relevant clinical parameters during treatment.